INHIBITION OF THE FACTOR XA (WITH RIVAROXABAN) SLOW DOWN PROGRESSION, PREVENTS COMPLICATION AND DECREASE MORTALITY IN CORONARY HEART DISEASE
A review presented, of the novel scientific data, mostly the results of large clinical trials, witnessing on clinical efficacy and safety of rivaroxaban — the anticoagulant, selective blocker of Xa factor — in treatment of acute and chronic coronary heart disease. The mechanisms explained, of the dr...
| 发表在: | Российский кардиологический журнал |
|---|---|
| 主要作者: | |
| 格式: | 文件 |
| 语言: | 俄语 |
| 出版: |
«FIRMA «SILICEA» LLC
2018-04-01
|
| 主题: | |
| 在线阅读: | https://russjcardiol.elpub.ru/jour/article/view/2753 |
| 总结: | A review presented, of the novel scientific data, mostly the results of large clinical trials, witnessing on clinical efficacy and safety of rivaroxaban — the anticoagulant, selective blocker of Xa factor — in treatment of acute and chronic coronary heart disease. The mechanisms explained, of the drug influence on atherothrombosis, especially the specifics of dosages and its combination with other antithrombotic drugs in various clinical situations. |
|---|---|
| ISSN: | 1560-4071 2618-7620 |